Does the media refer more to CRSP or ALLO?

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 6 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.88 beat Allogene Therapeutics' score of 0.59 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or CRSP?

In the previous week, Axsome Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 1.29 beat CRISPR Therapeutics' score of 0.88 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or CRSP?

In the previous week, Beam Therapeutics and Beam Therapeutics both had 6 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.88 beat Beam Therapeutics' score of 0.72 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EDIT or CRSP?

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 3 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat CRISPR Therapeutics' score of 0.88 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or KALA?

In the previous week, CRISPR Therapeutics had 5 more articles in the media than KALA BIO. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 1 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.88 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CRISPR Therapeutics (CRSP) Competitors

$47.99 -0.45 (-0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$48.24 +0.25 (+0.52%)

As of 07:43 PM Eastern

Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? MarketBeat compares CRISPR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA).

How does CRISPR Therapeutics compare to Allogene Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Allogene Therapeutics	N/A	-56.45%	-40.36%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,318.70	-$581.60M	-$6.22	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 6 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.88 beat Allogene Therapeutics' score of 0.59 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics currently has a consensus price target of $67.78, suggesting a potential upside of 41.23%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 353.31%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

CRISPR Therapeutics has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Axsome Therapeutics presently has a consensus price target of $261.29, indicating a potential upside of 19.86%. CRISPR Therapeutics has a consensus price target of $67.78, indicating a potential upside of 41.23%. Given CRISPR Therapeutics' higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Axsome Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 1.29 beat CRISPR Therapeutics' score of 0.88 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Axsome Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A
CRISPR Therapeutics	$3.51M	1,318.70	-$581.60M	-$6.22	N/A

Axsome Therapeutics has a net margin of -26.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 11 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Beam Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Beam Therapeutics presently has a consensus price target of $46.85, indicating a potential upside of 83.57%. CRISPR Therapeutics has a consensus price target of $67.78, indicating a potential upside of 41.23%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$164.01M	16.01	-$79.99M	-$0.68	N/A
CRISPR Therapeutics	$3.51M	1,318.70	-$581.60M	-$6.22	N/A

In the previous week, Beam Therapeutics and Beam Therapeutics both had 6 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.88 beat Beam Therapeutics' score of 0.72 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Editas Medicine presently has a consensus price target of $5.40, indicating a potential upside of 109.30%. CRISPR Therapeutics has a consensus price target of $67.78, indicating a potential upside of 41.23%. Given Editas Medicine's higher possible upside, equities research analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Editas Medicine has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 3 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat CRISPR Therapeutics' score of 0.88 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.23	-$160.06M	-$1.23	N/A
CRISPR Therapeutics	$3.51M	1,318.70	-$581.60M	-$6.22	N/A

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

CRISPR Therapeutics (NASDAQ:CRSP) and KALA BIO (NASDAQ:KALA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

CRISPR Therapeutics presently has a consensus target price of $67.78, indicating a potential upside of 41.23%. KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 153,138.96%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

KALA BIO has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,318.70	-$581.60M	-$6.22	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
KALA BIO	N/A	-1,336.10%	-94.85%

CRISPR Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its stock price is 335% less volatile than the broader market.

In the previous week, CRISPR Therapeutics had 5 more articles in the media than KALA BIO. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 1 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.88 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CRISPR Therapeutics beats KALA BIO on 11 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.63B	$3.52B	$6.83B	$12.41B
Dividend Yield	N/A	3.78%	2.59%	10.11%
P/E Ratio	-7.72	7.45	281.83	23.65
Price / Sales	1,318.70	1,262.85	585.86	92.89
Price / Cash	N/A	89.39	69.88	58.30
Price / Book	2.38	16.79	10.93	5.84
Net Income	-$581.60M	-$12.44M	$3.49B	$336.16M
7 Day Performance	3.12%	-1.48%	-0.30%	0.03%
1 Month Performance	-12.08%	-7.76%	-2.59%	-5.22%
1 Year Performance	-14.70%	49.26%	66.21%	17.37%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	2.8767 of 5 stars	$47.99 -0.9%	$67.78 +41.2%	-16.0%	$4.63B	$3.51M	N/A	460	Upcoming Earnings
ALLO Allogene Therapeutics	2.6035 of 5 stars	$1.75 +0.6%	$8.52 +387.0%	+52.7%	$604.01M	$20K	N/A	310	Positive News Analyst Forecast Gap Up
AXSM Axsome Therapeutics	3.6053 of 5 stars	$238.37 -1.1%	$261.48 +9.7%	+131.7%	$12.27B	$638.50M	N/A	380	Positive News Analyst Forecast
BEAM Beam Therapeutics	2.2705 of 5 stars	$25.07 -0.1%	$46.85 +86.9%	+31.5%	$2.58B	$139.74M	N/A	510	Upcoming Earnings Insider Trade
EDIT Editas Medicine	3.0479 of 5 stars	$2.68 +3.1%	$5.40 +101.5%	+6.7%	$262.39M	$38.69M	N/A	230	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Is CRSP or ALLO more profitable?

Do insiders & institutionals hold more shares of CRSP or ALLO?

Which has better earnings and valuation, CRSP or ALLO?

Does the media refer more to CRSP or ALLO?

Do analysts recommend CRSP or ALLO?

Which has more risk and volatility, CRSP or ALLO?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Do analysts rate AXSM or CRSP?

Does the media prefer AXSM or CRSP?

Do insiders and institutionals have more ownership in AXSM or CRSP?

Which has more risk and volatility, AXSM or CRSP?

Which has stronger earnings & valuation, AXSM or CRSP?

Is AXSM or CRSP more profitable?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Which has more risk and volatility, BEAM or CRSP?

Is BEAM or CRSP more profitable?

Do insiders and institutionals have more ownership in BEAM or CRSP?

Do analysts rate BEAM or CRSP?

Which has stronger earnings & valuation, BEAM or CRSP?

Does the media prefer BEAM or CRSP?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Do insiders and institutionals have more ownership in EDIT or CRSP?

Is EDIT or CRSP more profitable?

Do analysts rate EDIT or CRSP?

Which has more volatility & risk, EDIT or CRSP?

Does the media prefer EDIT or CRSP?

Which has higher earnings and valuation, EDIT or CRSP?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Do analysts prefer CRSP or KALA?

Which has stronger earnings and valuation, CRSP or KALA?

Do institutionals & insiders have more ownership in CRSP or KALA?

Is CRSP or KALA more profitable?

Which has more risk & volatility, CRSP or KALA?

Does the media favor CRSP or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools